Intranasal Therapeutics makes appointment
This article was originally published in Scrip
Executive Summary
Intranasal Therapeutics (US), a speciality pharmaceutical company developing nasally delivered preservative-free products, has named Dr Jeff Edelson executive vice-president of R&D and chief medical officer. He was previously employed by Johnson & Johnson as vice-president of internal medicine and therapeutic area head – novel therapeutics.